FindTrial
Sign In

A Compassionate Use (CU) Program of Odronextamab

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT05619367
Enrollment
Unknown
Registered
2022-11-16
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B-Cell Non-Hodgkin Lymphoma (NHL), Diffuse Large B-Cell Lymphoma (DLBCL), High-Grade B-Cell Lymphoma (HGBCL), Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Brief summary

Provide compassionate use of odronextamab

Interventions

DRUGOdronextamab

Sponsors

Regeneron Pharmaceuticals
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL

Contacts

Primary ContactRequests for compassionate use must be initiated by a treating physician Physicians should contact
CompassionateUseRequests@regeneron.com844-734-6643

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026